

## Review

# Autoantibodies as Endogenous Modulators of GPCR Signaling

Meredith A. Skiba<sup>1</sup> and Andrew C. Kruse  <sup>1,\*</sup>

Endogenous self-reactive autoantibodies (AAs) recognize a range of G-protein-coupled receptors (GPCRs). They are frequently associated with cardiovascular, neurological, and autoimmune disorders, and in some cases directly impact disease progression. Many GPCR AAs modulate receptor signaling, but molecular details of their modulatory activity are not well understood. Technological advances have provided insight into GPCR biology, which now facilitates deeper understanding of GPCR AA function at the molecular level. Most GPCR AAs are allosteric modulators and exhibit a broad range of pharmacological properties, altering both receptor signaling and trafficking. Understanding GPCR AAs is not only important for defining how these unusual GPCR modulators function in disease, but also provides insight into the potential use and limitations of using therapeutic antibodies to modulate GPCR signaling.

## Antibodies as GPCR Therapeutics

Over one hundred G-protein coupled receptors (GPCRs) are targeted by approved pharmaceuticals, making the family one of the most successful classes of drug targets [1]. Although biopharmaceuticals have gained popularity for therapeutic targeting of many other cell-surface molecules [2], GPCRs are almost exclusively targeted by small molecules. The unique pharmacokinetic and pharmacodynamic profiles and exceptional target specificity of biotherapeutics make antibodies compelling alternatives to small-molecule drugs [3]. For example, antibodies do not readily enter the central nervous system, permitting selective targeting of peripheral receptors, such as the adenosine A<sub>2a</sub> receptor, which plays distinct roles in neuronal and cardiac processes and immunity [4]. Additionally, antibodies can trigger targeted cytotoxic immune responses through their Fc regions, which may be desirable in certain indications. Current drug discovery efforts have produced therapeutic antibodies targeting GPCRs with large substrate-binding extracellular domains, which can serve as the antibody binding site, and chemokine receptors [5]. However, identifying functional antibodies remains highly challenging for the majority of GPCRs that lack large ectodomains and instead recognize their ligands directly within their transmembrane domains and extracellular loops. With few examples available, the capabilities and limitations of using antibodies to modulate GPCR signaling are largely unclear.

Endogenous self-antigen reacting antibodies, known as **autoantibodies (AAs)**, see [Glossary](#), have been detected for a wide range of GPCRs, including members of the adrenergic, muscarinic, angiotensin, and metabotropic glutamate families ([Figure 1](#), see Table S1 in the supplemental information online). The majority of AAs reported to date independently act as **agonists** and activate GPCRs, but they can both increase and decrease the **efficacy** of orthosteric agonists. In some cases, GPCR AAs induce noncanonical receptor-mediated activities. With the ability to alter a receptor's endogenous biology, GPCR AAs are often associated with disease and can be pathogenic. GPCR AAs could serve as scaffolds for future therapeutic antibody discovery efforts and may also provide valuable insight into how antibodies can be used to effectively modulate GPCR function.

## Highlights

Self-reactive antibodies (autoantibodies or AAs) are produced when there is a breakdown in the immune system's self-tolerance mechanisms and have been detected for 26 G-protein-coupled receptors (GPCRs). Despite considerable interest in therapeutic modulation of GPCRs with antibodies, little is known about the molecular function of AAs.

The vast majority of AAs described to date are functional and activate GPCR signaling, uncoupling receptors from endogenous signaling networks. Such modulation of signaling is often deleterious and many GPCR AAs are either known to be pathogenic or associated with disease.


AAs act allosterically and possess unique pharmacological properties, which often diverge from orthosteric agonists.

A dimeric antibody is often required for AA-induced receptor activation, suggesting that AAs may invoke an activation mechanism distinct from orthosteric agonists.

<sup>1</sup>Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA

\*Correspondence:  
[andrew\\_kruse@hms.harvard.edu](mailto:andrew_kruse@hms.harvard.edu)  
(A.C. Kruse).



**Glossary**

**Affinity maturation:** activated B cells undergo hypermutation-producing antibodies with increased affinity for the targeted antigen.

**Agonist:** a molecule that activates a receptor, stimulating a cellular response.

**Allosteric:** a binding site on a receptor that differs from where the endogenous ligand binds.

**Autoantibody (AA):** an endogenous antibody that recognizes a self protein, most frequently associated with autoimmune diseases.

**Biased signaling:** a phenomenon where an agonist preferentially activates one signaling outcome over another.

**Chagas' disease:** a parasitic infection characterized by acute flu like symptoms, which can cause chronic cardiovascular damage.

**Class A GPCR:** the largest family of GPCRs, which share sequence homology to rhodopsin. Members include aminergic, peptide, chemokine, and olfactory receptors.

**Class C GPCR:** a small class of GPCRs containing the mGluRs and  $\text{GABA}_{\text{B}}$  receptors, which contain large venus fly trap ectodomains and are obligate dimers.

**Class switching:** activated B cells can alter the isotype of the nonvariable region of an antibody through recombination, altering the antibodies function in the immune response.

**Efficacy:** the maximum strength of a signaling response.

**ELISA:** a method to detect the presence of an antibody for a specific antigen.

**Fab:** a monomeric fragment encoding the variable regions of an antibody required for antigen interactions.

**Natural AAs:** self-reactive antibodies present in healthy individuals.

**Paraneoplastic:** arising from cancer.

**Figure 1. G-protein-coupled receptor (GPCR) autoantibodies (AAs) Are Detected in a Variety of Conditions.** GPCR AAs are reported for 26 different GPCRs including the  $5\text{-HT}_2$  and  $5\text{-HT}_4$  serotonin receptors,  $\alpha_1$ ,  $\beta_1$ , and  $\beta_2$  adrenergic receptors ( $\beta_1\text{AR}$ ,  $\beta_2\text{AR}$ , and  $\alpha_1\text{AR}$ ), angiotensin II type I receptor ( $\text{AT}_1\text{R}$ ), calcium sensing receptor (CaSR),  $\text{D}_1$  and  $\text{D}_2$  dopamine receptors ( $\text{D}_1\text{R}$ ,  $\text{D}_2\text{R}$ ), endothelin type A receptor ( $\text{ET}_{\text{A}}\text{R}$ ),  $\text{GABA}_{\text{B}}$  receptor,  $\text{M}_1$ ,  $\text{M}_2$ ,  $\text{M}_3$ , and  $\text{M}_4$  muscarinic acetylcholine receptors ( $\text{M}_1\text{R}$ ,  $\text{M}_2\text{R}$ ,  $\text{M}_3\text{R}$ ,  $\text{M}_4\text{R}$ ), melanocortin-4 receptor ( $\text{MC}_4\text{R}$ ), metabotropic glutamate receptors 1, 2, and 5 ( $\text{mGluR}_1$ ,  $\text{mGluR}_2$ , and  $\text{mGluR}_5$ ), thyroid stimulating hormone receptor (TSHR), and  $\mu$ -opioid receptor (MOR). GPCR AAs are typically detected with ELISA, cell staining, radioligand binding, or functional bioassays.

(Figure legend continued at the bottom of the next page.)

## Generation of AAs

### Antibody-Mediated Immune Response

B cells display a massive repertoire of antibody clones in the form of B cell receptors (BCRs), which bind to specific antigens through their complementary determining regions (CDRs). Recognition of a protein antigen by the BCR induces internalization of the antibody–antigen complex and proteolysis of the antigen (Figure 2). Antigen peptides are displayed on the surface of B cells by MHC-II. Recognition of the MHC-II linked peptide by a peptide specific T cell receptor (TCR) induces a signaling cascade, which stimulates B cell proliferation, antibody **affinity maturation**, antibody **class switching**, and the secretion of antibodies into circulation [6].

In order to suppress inappropriate immune responses to endogenous proteins, developing B cells and T cells undergo clonal selection to remove self-reactive BCRs and TCRs. The autoimmune regulator (AIRE) transcription factor promotes low level expression of many proteins not typically resident in the thymus allowing TCRs to broadly sample endogenous peptides. Self-reactive T cells are eliminated [7]. Similarly, contact with a self-antigen in early B cell development triggers genetic recombination of the antibody to reduce self-reactivity. If self-reactivity persists, apoptosis occurs [8].


### GPCR AAs in Healthy Individuals

Clonal selection of the immune repertoire requires a fine balance; self-reactivity must be avoided without relinquishing the ability to effectively respond to a diverse range of antigens. Despite clonal selection, some self-reactive T cells and B cells leave the thymus and bone marrow, and many are maintained in an anergic state through peripheral tolerance mechanisms [9]. Still, low levels of **natural AAs** are present in healthy individuals, including antibodies recognizing GPCRs [10]. Some GPCR AAs detected in healthy individuals are apparently nonfunctional [11–14]. However, AAs recognizing the  $\mu$ -opioid and  $\delta$ -opioid receptors, isolated from therapeutic intravenous immunoglobulin pooled from thousands of apparently healthy donors or single healthy donors, activate G-protein signaling [15–17]. AAs targeting the endothelin type A receptor (ET<sub>A</sub>R) in healthy individuals promote neutrophil migration through a receptor dependent mechanism [10]. Furthermore, natural AAs targeting the CCR5 chemokine receptor, a coreceptor for HIV-1, are found in a subset of healthy individuals and some individuals who are infected with HIV and do not receive antiretroviral therapy, but do not progress to AIDS [18,19]. CCR5 AAs inhibit binding of the endogenous ligand Mip1 $\beta$  (CCL4) to the receptor [19] and block HIV viral entry [18,20,21], neutralizing viral infection [19,22,23]. Thus, not all GPCR AAs are pathogenic and, in some cases, can be beneficial.

### Loss of Self-Tolerance and Production of GPCR AAs

The majority of disease-associated GPCR AAs arise through B cell activation and the subsequent antibody maturation process. The production of high-affinity AAs can result from crossreactivity between foreign and self-antigens (molecular mimicry); alterations to the self-antigen through post-translational modification; exposure of immunologically privileged antigens through tissue damage; increased inflammatory signals; or deficiencies in self-tolerance mechanisms [7,8,24]. Several of these mechanisms are linked to the production of GPCR AAs. Placental damage and exposure to inflammatory cytokines stimulates the production of AAs targeting the angiotensin II type I receptor (AT<sub>1</sub>R) in a rat model of pre-eclampsia [25]; a pregnancy-related hypertensive disease and a leading cause of maternal and fetal morbidity [26]. Molecular mimicry between ribosomal proteins from the parasite *Trypanosoma cruzi*, the causative agent of **Chagas' disease**, and the  $\beta_1$  adrenergic receptor ( $\beta_1$ AR) produce antibodies cross reacting with *T. cruzi* proteins and the  $\beta_1$ AR [27–29]. Similarly, exposure to *Streptococcus pyogenes* produces antibodies

GPCR AAs that influence receptor-mediated signaling events are bolded. See Table S1 in supplemental information online for additional information on AA epitopes and functional effects of AAs. Abbreviations: PANDAS, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.



**Figure 2. Antibody Production Requires Input from B Cells and T Cells.** (A) Antigens are recognized by the B cell receptor (BCR), a membrane-tethered antibody. The bound antigen is internalized and proteolyzed. (B) Proteolyzed antigen is loaded into MHC-II and trafficked to the B cell surface. (C) The MHC-II-bound peptide is recognized by a peptide-specific T cell receptor (TCR) on the surface of a CD4<sup>+</sup> helper T cell. A series of coactivating interactions between the T cell and B cell, such as the engagement of CD40 with CD40L, trigger the release of cytokines, which initiates B cell activation and antibody maturation. (D) Activated B cells differentiate into antibody-secreting plasma cells to immediately respond to the antigen and memory B cells, which preserve the immune response.

recognizing both bacterial antigens and the D<sub>2</sub> dopamine receptor [30]. Mutations in the transcription factor AIRE, which regulates T-cell receptor self-tolerance, results in autoimmune polyendocrine syndrome type 1 (APS1, also known as APCED). Individuals with this syndrome are prone to developing AAs for the calcium-sensing receptor (CaSR), which alter calcium homeostasis and cause hypoparathyroidism [31].

The events triggering the production of many GPCR AAs are unidentified. For example, AAs targeting the metabotropic glutamate receptor (mGluR)<sub>5</sub> are linked to neurological symptoms such as memory loss in individuals with Hodgkin's lymphoma [32,33]. These cognitive symptoms that are likely caused by mGluR<sub>5</sub> AAs decline with successful cancer treatment [32]. Therefore, mGluR<sub>5</sub> AA production may be **paraneoplastic** and occur as a response to aberrant receptor expression on the cancer cells [32,33], but the exact antibody-generating stimulus remains


unknown. In other cases, the ongoing immune response to a self-antigen can trigger the production of AAs for additional self-antigens through epitope spreading [34], which may account for correlating levels of GPCR AAs targeting multiple receptors in some diseases [10].

### Pathological Role of GPCR Targeting AAs

As GPCRs regulate many aspects of biology (Box 1), alterations to canonical GPCR signaling mechanisms by AAs often have pathological consequences. In order to classify an AA as a causative agent of disease, an AA must recapitulate features of the disease in an animal model as defined by Witebsky's postulates for autoimmune diseases [35]. Titers of GPCR AAs are often low and the sequence of most GPCR AAs are unknown making it difficult to perform such experiments with endogenous AAs. Often evidence for the pathological role of AAs is gathered by replicating the immune response through exposure of an animal to antibody-accessible extracellular regions of the receptor to produce AAs that share many of the activities of the human AA (AA mimics) (Table 1). AA mimics produced via immunization of animals with peptides derived from the

#### Box 1. Canonical GPCR Signaling

GPCRs are dynamic proteins that fluctuate between a range of functional states with varying affinities both orthosteric ligands and intracellular signal transducers. In canonical signaling pathways, the binding of an endogenous or synthetic agonist to the receptor triggers a conformational change within the receptor's seven transmembrane domain, which recruits heterotrimeric G-proteins containing  $G_{\alpha}$ ,  $G_{\beta}$ , and  $G_{\gamma}$  subunits and promotes exchange of GDP to GTP in the  $G_{\alpha}$  subunit. The activated G proteins dissociate from the receptor and induce a series of downstream signaling events that elicit a biological response (Figure 1). G-protein signaling is attenuated through receptor phosphorylation by GPCR kinases and the recruitment of  $\beta$  arrestins, which sterically hinder interactions between GPCRs and G proteins and promote receptor internalization. In addition to their role in desensitization,  $\beta$  arrestins initiate G-protein-independent signaling cascades (Figure 1). Agonists that preferentially activate G-protein-dependent or -independent signaling pathways are known as biased agonists.



Trends in Pharmacological Sciences

**Figure 1. G-Protein-Coupled Receptors (GPCRs) Induce a Variety of Downstream Signaling Cascades.** GPCRs are stimulated by a wide range of agonists, including small molecules, peptides, and proteins such as antibodies, and they regulate many biological processes. Downstream signaling is mediated by the  $G_{\alpha}$ ,  $G_{\beta}$ , and  $G_{\gamma}$  subunits of heterotrimeric G proteins. Sixteen  $G_{\alpha}$  subunits are encoded by four families ( $G_s$ ,  $G_{i/o}$ ,  $G_{q/11}$ , and  $G_{12/13}$ ), each of which engages a distinct signaling cascade [75]. Additionally, four different  $G_{\beta}$  subunits and 12  $G_{\gamma}$  subunits stimulate additional signaling pathways [116]. Recruitment of  $\beta$  arrestins suppress G-protein signaling, and initiates G-protein-independent signaling cascades, primarily through mitogen-activated protein kinase (MAPK) pathways [117]. Abbreviations: DAG, diacylglycerol; GEF, guanine exchange factor; GIRK channel, G-protein-coupled inwardly-rectifying potassium channel; IP3, inositol triphosphate; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC, phospholipase C.

Table 1. GPCR AAs Identified as Pathogenic

Receptor	Syndrome	Method	Pathology	Refs
$\beta_1$ AR	Cardiomyopathy	ECL2 peptide immunization	Increased heart weight Enlarged left and right ventricles Decreased right and left ventricle wall thickness <b>Cardiac degeneration and inflammation</b>	[36]
		ECL2 peptide immunization	Left ventricular hypertrophy	[119]
		ECL2 peptide immunization	Left ventricular dilation and dysfunction Increased heart mass	[37]
		Passive transfer	Left ventricular dilation and dysfunction Increased heart mass	[37]
		ECL2 peptide immunization	Left ventricular dilation Decrease in fractional shortening	[120]
		ECL2 peptide immunization	Cardiac electrical remodeling	[121]
$M_2$ R	Atrial fibrillation	ECL2 peptide immunization	Altered cardiac electrophysiology <b>Atrial fibrosis</b>	[122]
	Cardiomyopathy	ECL2 peptide immunization	Enlarged right ventricle Decreased right ventricular wall thickness <b>Cardiac degeneration and inflammation</b>	[36]
		ECL2 peptide immunization	Decreased myocardial contractility Decreased diastolic function Ventricular dilation and wall thinning	[123]
		ECL2 plasmid immunization	Reduced left ventricular wall thickness Reduced ejection fraction	[124]
		Passive transfer	Reduced left ventricular wall thickness Reduced ejection fraction	[124]
$M_3$ R	Sjögren's syndrome	Passive transfer	<b>Overactive bladder</b>	[125]
		Passive transfer	Decreased saliva volumes	[126]
$AT_1$ R	Cardiovascular disease	ECL2 peptide immunization	Cardiac hypertrophy Increased blood pressure <b>Increased heart rate</b>	[127]
	Pre-eclampsia	Passive transfer	Hypertension Proteinuria Glomerular endotheliosis Placental abnormalities Small fetal size <b>Increased levels of soluble fms-related tyrosine kinase-1 (sFlt1)</b>	[39]
		Passive transfer	Increased blood pressure <b>Production of endothelin-1</b>	[128]
		Passive transfer	<b>Increased sensitivity to AngII</b>	[129]
		Passive transfer	Increased blood pressure <b>Increased sFlt1</b> <b>Increased sEndoglin</b>	[130]
		Passive transfer	Increased blood pressure <b>Increased oxidative stress</b>	[131]
		Passive transfer	Increased blood pressure <b>Increased sensitivity to AngII</b>	[132]
$ET_{\text{A}}$ R	Pulmonary arterial hypertension	Passive transfer	<b>Diminished peripheral vasculature</b> <b>Dilated pulmonary arteries</b> Right ventricular hypertrophy <b>Vascular remodeling</b>	[133]

Table 1. (continued)

Receptor	Syndrome	Method	Pathology	Refs
MC <sub>4</sub> R	Obesity	N-terminal peptide immunization	Increased body weight Increased food intake Increased plasma triglyceride levels	[134]
		Passive transfer	Increased food intake	[134]
		Passive transfer	Increased food intake	[135]
TSHR	Grave's disease	Passive transfer	Thyroid hormone secretion	[136]
		Passive transfer	Thyroid hormone secretion Inhibition of thyroid hormone secretion	[137]
mGluR <sub>1</sub>	Cerebellar ataxia	Passive transfer	Ataxia	[40]

extracellular loops of  $\beta_1$ AR induce many of the pathologies found in individuals with  $\beta_1$ AR-AA-associated cardiomyopathy, confirming  $\beta_1$ AR AAs as cardiotoxic [36,37]. More complete evidence for a causative role of  $\beta_1$ AR AAs in cardiomyopathy comes from passive transfer experiments, where exposure of healthy mice to  $\beta_1$ AR AAs induces cardiac damage [37]. Similar experiments implicate AT<sub>1</sub>R AAs in the development of pre-eclampsia [38], as transfer of AT<sub>1</sub>R AAs from a pre-eclamptic human patient to healthy pregnant mice induced many of the symptoms of pre-eclampsia. Blockade of the AA interaction with AT<sub>1</sub>R prevents the development of the disease [39]. Similarly, mice treated with AAs targeting mGluR<sub>1</sub> from individuals with coordination deficiencies caused by paraneoplastic cerebellar ataxia develop analogous neurological symptoms [40].




## Effects of AAs at the Molecular Level

### Identification of Extracellular Epitopes

Binding and neutralization experiments have defined epitopes on the extracellular surface of GPCRs involved in AA binding. AAs interacting with **class C GPCRs** or glycohormone GPCRs can activate or inhibit receptor function through interactions with the receptor's large N-terminal ectodomains. Interaction of an AA with the thyroid-stimulating hormone receptor (TSHR) ectodomain activates the receptor and causes hyperthyroidism associated with Graves' disease. A second TSHR AA binds a distinct, yet overlapping, region of the ectodomain and suppresses basal signaling, which results in hypothyroidism (Figure 3A) [41,42]. A third type of TSHR AA interacts with a region of the receptor that undergoes intramolecular cleavage, interrupting processing of the receptor and consequently function [43]. Similarly, AAs binding the extracellular venus flytrap domain of the class C CaSR can positively or negatively regulate receptor function resulting in either hypocalcemia or hypercalcemia [44,45].

**Class A GPCRs**, which mostly lack structured ectodomains, have an N terminus of variable length and three extracellular loops (ECLs) accessible to antibodies. ECL1 is short and portions of the loop are buried, including a conserved tryptophan that packs against a conserved disulfide bond between ECL2 and transmembrane helix three. ECL2 is the largest of all three ECLs and one of the most distinct features of Class A GPCRs both in sequence and structure (Figure 3B–D). Largely exposed, ECL2 lines the entrance to the orthosteric ligand binding site and can rearrange upon agonist binding. In some cases, such as in many peptide receptors, ECL2 directly interacts with agonists. ECL3 is variable and exposed, but typically short, sometimes unstructured, and not associated with activation-related conformational changes.

All three ECLs have been implicated in AA binding to class A GPCRs. The most predominant epitope for functional AAs is ECL2 (Figure 3B–D, Table S1) [46–53], but interactions with ECL1 and ECL3 are crucial for the function of a few AAs [17,46,53–55]. As ECL2 is variable in sequence



Trends in Pharmacological Sciences

(See figure legend at the bottom of the next page.)

even among subtypes of receptors, AAs may readily achieve subtype selectivity. AT<sub>1</sub>R AAs from women with pre-eclampsia interact with the C-terminal portion of ECL2 (Figure 3B, amino acids 181–187) [51] that directly interacts with the endogenous peptide ligand angiotensin II (AngII) (Figure 3B) [56]. While this suggests that AT<sub>1</sub>R AAs in individuals with pre-eclampsia may directly interfere with the binding of orthosteric ligands, ECL2 binding AT<sub>1</sub>R AAs from hypertensive patients are not reported to effect AngII binding [57]. β<sub>1</sub>AR AAs studied in individuals with Chagas' cardiomyopathy and dilated cardiomyopathy bind to adjacent regions of ECL2 (amino acids 201–205 and 206–218, Figure 3C) [27,46], and confer similar physiological effects (Figure 3C). Binding studies with AAs for the M<sub>2</sub> muscarinic receptor (M<sub>2</sub>R) demonstrate that M<sub>2</sub>R AAs are competitive with the allosteric modulator gallamine, which occupies a well-characterized allosteric site for muscarinic receptors [58–61], and partially reverse gallamine's ability to attenuate orthosteric ligand dissociation [62]. Allosteric modulators of muscarinic receptors mediate their effects by binding to the extracellular vestibule of the orthosteric ligand-binding site, which includes ECL2 (Figure 3D). The ECL2 binding M<sub>2</sub>R AAs may share some of the functionalities of muscarinic allosteric modulators and alter access to the orthosteric site, but as M<sub>2</sub>R AAs do not slow orthosteric ligand dissociation to the same extent as gallamine, the AAs may not fully occupy the allosteric site [62].

#### GPCR AAs as Allosteric Modulators


Allosteric ligands influence coupling of GPCRs to G proteins and β arrestins by altering the ability of agonists or antagonists to bind to the orthosteric site or directly influencing the receptor's global conformation (Box 2) [63], conferring distinct pharmacological properties to allosteric modulators. While extensive pharmacological characterization is needed to fully define how AAs influence GPCR function, several observations support an allosteric mechanism as a general feature of most GPCR-targeting AAs. Generally, activating AAs for adrenergic and muscarinic receptors displace radiolabeled antagonists in a noncompetitive manner, typically decreasing the number of available antagonist binding sites with little to no effect on antagonist affinity [64–71]. This means that these AAs do not directly compete for the orthosteric site of the receptor, but likely induce the receptor to more frequently sample active or active-like receptor states that are not compatible with antagonist binding and favor transducer binding. At equilibrium, this manifests as an overall reduction in antagonist-accessible binding sites. Further support for the possibility of AAs directly influencing receptor conformation is seen in agonist competition binding experiments performed in the presence of G proteins and AAs. G proteins typically produce an additional high-affinity agonist binding state in addition to that of the lower-affinity uncoupled receptor [72]. Similar to exposure to an orthosteric agonist or nucleotide addition, preincubation of the M<sub>2</sub>R with M<sub>2</sub>R AAs fully leads to release of the G protein and diminishes the high affinity G-protein-coupled component of agonist binding [67]. In addition, bioluminescence resonance energy transfer (BRET) studies demonstrate AA-induced conformational change in the β<sub>1</sub>AR [12].

Like other allosteric modulators, the effects of AAs in the presence of an orthosteric agonist are distinct from those on the unliganded receptor (Table S1). Activating GPCR AAs can both

**Figure 3.** Antigen Recognition by G-Protein-Coupled Receptor (GPCR) Autoantibodies (AAs). (A) The thyroid-stimulating hormone receptor (TSHR) contains an N-terminal leucine-rich repeat (LRR) ectodomain [colored as a rainbow, from blue (N terminus) to red (C terminus)] that binds the receptor's endogenous agonist thyroid stimulating hormone (TSH). TSHR AAs interfere with TSH binding by interacting with the LRR. Despite recognizing adjacent regions, TSHR AAs both activate (PDB: 3G04 [41]) and suppress (PDB: 2XWT [42]) receptor signaling. (B–D) AA epitopes and extracellular loop 2 (ECL2) sequence alignments. (B) Phe182 and Tyr184 in the ECL2 epitope (green) recognized by angiotensin II type I receptor (AT<sub>1</sub>R) AAs interacts with the receptor's endogenous peptide agonist angiotensin II (pink) through backbone interactions (PDB: 6OS0 [56]). (C) ECL2 (pink, PDB: 2VT4 [118]), a common epitope for adrenergic receptor AAs, is highly divergent among receptor subtypes. (D) The ECL2 binding site for M<sub>2</sub> AAs (blue, PDB: 4MQT [58]) overlaps with a known allosteric regulatory site (teal) for muscarinic receptors.

## Box 2. Allosteric Modulation of GPCR Signaling

By binding outside the orthosteric binding site, allosteric modulators can both positively and negatively influence the affinity of orthosteric ligands and modulate a receptor's ability to couple transducers. The combination of these independent effects yields varied outcomes on the intrinsic efficacy (signaling strength) of an orthosteric ligand. In the operational model describing orthosteric ligand–receptor interactions, the effects of allosteric modulators on ligand affinity and the transducer coupling are described by the cooperativity factors  $\alpha$  and  $\beta$  (Figure 1) [63]. Individually, coupling of the allosteric modulator or orthosteric ligand elicit distinct signaling response. Combined, the allosteric and orthosteric ligand can influence one another to elicit a new signaling response, that differs from the allosteric or orthosteric ligand alone. The cooperativity factors for allosteric modulators are dependent on the identity of the orthosteric ligand, which can result in varied effects on the efficacy of different orthosteric agonists or in the absence of ligand.



**Figure 1. Influence of Allosteric Molecules on the Operational Model of Ligand–Receptor Interactions.** (A) The cooperativity factors  $\alpha$  and  $\beta$  define the effects of the allosteric modulator (A) on the orthosteric ligand (O).  $\alpha$  is a measure of the effect of the orthosteric and allosteric ligands on their respective equilibrium constants ( $K_O$  and  $K_A$ ).  $\beta$  describes the effect of the allosteric modulator on the signaling response (S). (B) When  $\alpha > 1$  (purple) the allosteric ligand potentiates signaling, whereas  $\alpha < 1$  (pink) suppresses signaling in response to the orthosteric ligand. When  $\alpha = 1$  the allosteric modulator has no effect on the activity of the orthosteric ligand (blue). (C)  $\beta$  describes the effect of the allosteric modulator on the efficacy or intensity of the signaling response (blue). When  $\beta > 1$  the level of signaling is increased (purple), but when  $\beta < 1$  a decreased response occurs (pink). The values of  $\alpha$  and  $\beta$  are independent of one another; an allosteric ligand with  $\alpha > 1$  can have a  $\beta < 1$ .

positively and negatively modulate the activity of orthosteric agonists (Box 2). Nearly all functional  $\beta_1$ AR AAs recognize an ECL2 epitope and result in activation of adenylyl cyclase. Despite these shared features, the effects of  $\beta_1$ AR AAs on ligand efficacy diverge, with most suppressing [65,68,73,74], but some enhancing [68,69] agonist-induced cAMP production.

### Unique Pharmacology of GPCR-AAs

#### AAs Influence G-Protein Selectivity

Many GPCRs display a preference for one of four classes of G $\alpha$  transducer subunits (G $s$ , G $i/o$ , G $q/11$ , and G $12/13$ ), but can exhibit varying degrees of promiscuity [75,76]. Like orthosteric ligands, AAs can influence G protein selectivity. The  $\beta_2$ AR primarily activates G $s$ -mediated signaling to stimulate cAMP production, but it can also couple to G $i$  [77]. While the majority of  $\beta_2$ AR AAs stimulate cAMP [47,78],  $\beta_2$ AR AAs derived from a subset of individuals with heart failure decreased cAMP production [79]. As the addition of pertussis toxin (PTX), a G $i$  inhibitor, suppressed AA activity, these  $\beta_2$ AR AAs are not simply acting as inverse agonists, but rather activate G $i$  [79]. An analogous negative inotropic effect induced by  $\beta_2$ AR AAs on myocardial contractility was reversed by  $\beta_2$ AR antagonists [80]. In this example, G $i$ -mediated activity is suspected, but not confirmed. Protein kinase A (PKA)-mediated phosphorylation of  $\beta_2$ AR has been shown to promote coupling to G $i$  [77], suggesting that the AAs may stabilize a receptor state that promotes PKA phosphorylation.  $\beta_2$ AR AAs that activate either G $s$  or G $i$  bind to ECL2 [47,78,79]. This suggests that antibodies binding to similar extracellular regions of a GPCR can exhibit divergent signaling biology. AAs recognizing the 5-hydroxytryptamine 2A receptor (5-HT<sub>2A</sub>) also alter G-protein selectivity. Some 5-HT<sub>2A</sub> AAs activate G $q$  signaling pathways to cause neurotoxic effects [81,82]. However, AAs from a subset of individuals with schizophrenia elicit 5-HT<sub>2A</sub>-mediated neuroprotection, which is sensitive to PTX, indicative of G $i$  coupling [81]. Finally, an AA from an individual with acquired hypocalciuric hypercalcemia targeting the CaSR, which activates both G $q$  and G $i$ , potentiates the G $q$ -mediated generation of inositol phosphate, but suppresses G $i$ -mediated extracellular signal-regulated kinase (ERK) 1/2 phosphorylation [83]. Effects of the G $q$ -biased CaSR-AAs, which bind to the receptor's extracellular venus flytrap domain, are reversed by binding of the CaSR-positive allosteric modulator cinacalcet to the receptor's 7-TM domain [84], further linking the action of ectodomain binding AAs to transducer coupling.

#### Activation of Noncanonical Signaling Pathways by AAs

In addition to altering canonical G-protein-mediated pathways, AAs can support signaling through mechanisms that differ from orthosteric agonists. For example, a  $\beta_1$ AR AA delays activation of downstream mitogen-activated protein kinase (MAPK) signaling. Unlike orthosteric agonists,  $\beta_1$ AR-AA-induced ERK 1/2 phosphorylation is sensitive to an Src kinase inhibitor [85], suggestive of G $i$ -coupled G $\beta\gamma$ -dependent MAPK activation [86]. However, PTX is not inhibitory, indicating that the AA is invoking an alternative MAPK activation network. Although MAPK activity is not dependent on receptor endocytosis [85], this  $\beta_1$ AR AA may support  $\beta$ -arrestin-based MAPK activity, which also stimulates ERK activity through Src [87]. While the mechanism of  $\beta_1$ AR-AA-induced ERK activation is not fully understood, it is clear that it differs from those of orthosteric agonists.

#### GPCR AAs Prolong Signaling

Activated GPCRs normally undergo both rapid desensitization that suppresses G-protein signaling cascades and long-term desensitization that provides temporal control to signaling responses and results in tachyphylaxis in response to clinically used agonists [88,89]. Rapid desensitization is largely mediated by the recruitment of arrestin and subsequent receptor internalization, whereas long-term desensitization is controlled by receptor expression and degradation. For typical agonists, rapid desensitization occurs within minutes of receptor activation. AAs targeting the  $\beta_1$ AR,  $\alpha_1$ AR, M<sub>2</sub>R, and ET<sub>AR</sub> sustain GPCR signaling for hours and do not undergo rapid desensitization

[49,74,90]. Prolonged signaling by AAs is not indefinite, as long-term desensitization mechanisms may still function [91]. Deficiencies in short-term desensitization could arise from reduced engagement of  $\beta$  arrestins, which is characteristic of G-protein-**biased signaling**. Overall, the effects of AAs on  $\beta$ -arrestin recruitment are not well established and appear to be variable. Murine  $\beta_1$ AR AA mimics and  $M_2$ R AAs from individuals with Chagas' disease were incapable of recruiting  $\beta$  arrestins [92,93], but an  $M_3$ R AA from an individual with postural hypotension promoted  $\beta$ -arrestin recruitment [78]. Similarly,  $AT_1$ R AAs from pre-eclamptic women do not support  $\beta$ -arrestin recruitment [94], but  $AT_1$ R AAs from individuals with postural orthostatic tachycardia syndrome stimulate recruitment of  $\beta$  arrestin [95]. The lack of  $\beta$ -arrestin recruitment to the  $AT_1$ R is surprising as it strongly couples to  $\beta$  arrestin in response to agonist-induced signaling [96] and G-protein-biased orthosteric ligands for  $AT_1$ R retain the ability to recruit arrestin [97]. This discrepancy in  $\beta$ -arrestin recruitment by AAs could be explained by different compositions of polyclonal AAs in the two patient groups or perhaps reduced or delayed  $\beta$ -arrestin recruitment mechanism, which may not be observed in all assay setups. Reports of the effect of AAs on receptor internalization are also varied with AAs for the same receptor both causing and suppressing internalization [12,49,67,98].

#### Effect of GPCR AAs on Receptor Trafficking

Once internalized, interactions between GPCR and  $\beta$  arrestins influence canonical receptor trafficking, with weak interactions between receptors and  $\beta$  arrestins promoting rapid recycling back to the membrane and strong interactions that prolong endosomal residence times prior to recycling or degradation [96]. AAs, which permit receptor internalization, also influence receptor trafficking. However, the role of  $\beta$  arrestins in AA-mediated receptor internalization is often undefined. Compared with endogenous agonists that stimulate rapid CCR5 internalization and recycling [99], CCR5 AAs induce slow clathrin-mediated internalization, depleting CCR5 from the cell surface over 48 h [23]. Protein synthesis is required for the repopulation of CCR5 at the cell surface, suggesting that internalized AA-CCR5 complexes are not recycled [100]. Similarly, AA-mediated internalization of  $\beta_1$ AR results in a loss of receptor recycling and presumably receptor degradation [98]. A loss of receptor recycling pathways may account for the downregulation of mGluR<sub>5</sub> expression after exposure to AAs [101].

#### Receptor Dimerization in AA-Induced Signaling

While the role of oligomerization in endogenous GPCR signaling is debated [102], dimerization is required for the agonistic activity of several AAs. Conversion of a dimeric  $\beta_1$ AR AA to a monovalent **Fab** fragment results in a loss of agonistic activity [103]. Similarly,  $M_2$ R-AA Fab fragments do not reduce the efficacy of orthosteric agonists like full-length AAs [93]. An analogous phenomenon is observed with murine monoclonal AA mimics for  $\beta_1$ AR [92],  $\beta_2$ AR [104], and  $M_2$ R [105], where Fab fragments do not possess the agonistic effects of the full-length antibodies. In some cases, the AA Fab fragment acts as a receptor antagonist [104]. Crosslinking the AA Fabs with an anti-mouse IgG restored the AA's agonistic effects [104,105], confirming the oligomeric requirement for AA-induced signaling. However, the specific interaction between the AA and receptor is crucial for activity, as the addition of a receptor-dimerizing anti-FLAG antibody is not sufficient for activation of FLAG-tagged  $\beta_1$ AR [92]. The functional requirement for receptor dimerization in AA-mediated receptor activation is surprising, since monomeric  $\beta_2$ AR is fully capable of activating G proteins [106]. While additional biochemical and structural analysis is needed to understand the role dimerization plays in AA-mediated signaling, receptor activation by AAs could be similar to activation of dimeric class C GPCRs, where interactions between the ectodomain and ECL2, and between transmembrane helix 6 of each receptor monomer stabilize the active state [107–109]. Still, receptor dimerization is not necessary for all AA-mediated signaling, as a murine monoclonal antibody that crossreacts with ECL2 of both  $\beta_1$ AR and  $M_2$ R acts as an agonist as a full-length antibody and a monomeric Fab fragment [110].

## Concluding Remarks and Future Perspectives

Decades of research have identified and provided initial characterization of functionally modulatory GPCR AAs. Still, there are countless unanswered questions regarding the mechanistic basis of GPCR-AA action and pathological role of GPCR AAs (see Outstanding Questions). Conflicting reports on the prevalence of GPCR AAs complicate correlating the presence of AAs with disease. Some discrepancies are a result of experimental differences [111]. Much work has relied on peptide-based **ELISAs**, which are subject to false-positive results due to polyreactivity [69], do not detect antibodies recognizing 3D conformational epitopes, and are not reflective of GPCR-AA bioactivity [112]. Thus, the true frequency of functional GPCR AAs is unknown. The majority of GPCR AAs described in the literature are antibody agonists. It is possible that GPCR-AA antagonists exist but have largely gone undetected, since they may not show any clear effect in a signaling assay in the absence of agonist. The increased use of ELISAs with membrane extracts containing overexpressed receptors [13] and development of standardized GPCR-AA ELISA assays (Cell-Trend) is a step towards consistency and may also allow identification of antagonistic or functionally neutral AAs. However, functional assays are critical for determining the potential pathogenicity of AAs. As many AAs are not abundant, increased application of highly sensitive secondary messenger assays [113] or assays relying on amplified signals, such as transcriptional readouts or bioassays are ideal for identifying functional AAs in patient samples. Defining the functionality of GPCR-AAs is especially essential for understanding the significance of natural GPCR AAs detected in healthy individuals.

Like other allosteric modulators, GPCR AAs have distinct and complex pharmacological properties. The development of new technologies for studying both antibodies and GPCRs will certainly facilitate in-depth mechanistic studies of GPCR AAs to fully understand their biology. The majority of work characterizing GPCR AAs has been performed with polyclonal patient samples or animal AA mimics produced through immunization. Limited access to patient-derived samples puts limitations on both the quantity and types of experiments used to study GPCR AAs. Single-cell techniques commonly used to identify and clone rare virus-neutralizing antibodies [114] in combination with advances in preparing GPCR antigens for antibody discovery efforts [5] could rapidly identify patient-derived monoclonal GPCR-AA. Unlimited access to patient-derived monoclonal GPCR AAs will enable detailed structure-function studies using lipidic cubic phase crystallography and serial crystallography techniques, as well as cryo-electron microscopy [115], to determine the mechanism by which antibodies activate GPCRs. Additionally, access to monoclonal samples will facilitate full pharmacological profiling of GPCR AAs.

Overall, GPCR AAs are an untapped resource for studying how allosteric antibodies can influence GPCR biology. While prior research has provided many intriguing hints regarding their function, additional insight into the action of GPCR AAs could provide essential information for the development of antibody therapeutics, including noncanonical effects on receptor signaling and trafficking that could be advantageous or detrimental to drug development.

## Acknowledgments

We would like to thank Morgan Gilman and Niranjan Varma for critical reading of the manuscript. Figures were prepared using BioRender. This work was supported by National Institutes of Health (NIH) grant R21HD101596 (A.C.K.) and a Merck Postdoctoral Fellowship from the Helen Hay Whitney Foundation (M.A.S.).

## Disclaimer Statement

A.C.K. is a cofounder and consultant for Tectonic Therapeutic Inc. and for the Institute for Protein Innovation, a nonprofit research institute.

## Supplemental Information

Supplemental information associated with this article can be found online <https://doi.org/10.1016/j.tips.2020.11.013>.

## Outstanding Questions

What is the true prevalence of functional AAs in both healthy individuals and disease states?

How are interactions with AAs and the extracellular loops transduced through the receptor core to activate G proteins?

Do AAs stabilize receptor conformations that differ from orthosteric agonist-bound states?

Why is dimerization often required for AA-mediated receptor activation?

Do AAs frequently induce biased signaling?

Are there distinct trafficking pathways for internalized AA-GPCR complexes?

## References

1. Hauser, A.S. *et al.* (2017) Trends in GPCR drug discovery: new agents, targets and indications. *Nat. Rev. Drug Discov.* 16, 829–842
2. Rodgers, K.R. and Chou, R.C. (2016) Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions. *Biotechnol. Adv.* 34, 1149–1158
3. Hutchings, C.J. *et al.* (2017) Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. *Nat. Rev. Drug Discov.* 16, 661
4. Fredholm, B.B. *et al.* (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors – an update. *Pharmacol. Rev.* 63, 1–34
5. Hutchings, C.J. (2020) A review of antibody-based therapeutics targeting G protein-coupled receptors: an update. *Expert. Opin. Biol. Ther.* 20, 925–935
6. Parkin, J. and Cohen, B. (2001) An overview of the immune system. *Lancet* 357, 1777–1789
7. Theofilopoulos, A.N. *et al.* (2017) The multiple pathways to autoimmunity. *Nat. Immunol.* 18, 716–724
8. Nemazee, D. (2017) Mechanisms of central tolerance for B cells. *Nat. Rev. Immunol.* 17, 281–294
9. Richards, D.M. *et al.* (2016) Re-examining the nature and function of self-reactive T cells. *Trends Immunol.* 37, 114–125
10. Cabral-Marques, O. *et al.* (2018) GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. *Nat. Commun.* 9, 5224
11. Chiale, P.A. *et al.* (1995) High prevalence of antibodies against  $\beta_1$ - and  $\beta_2$ -adrenoceptors in patients with primary electrical cardiac abnormalities. *J. Am. Coll. Cardiol.* 26, 864–869
12. Bornholz, B. *et al.* (2013) Impact of human autoantibodies on  $\beta_1$ -adrenergic receptor conformation, activity, and internalization. *Cardiovasc. Res.* 97, 472–480
13. Riemeeksterk, G. *et al.* (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. *Ann. Rheum. Dis.* 70, 530–536
14. Fu, L.X. *et al.* (1993) Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. *J. Clin. Invest.* 91, 1964–1968
15. Ranganathan, P. *et al.* (2009) Autoantibodies to the  $\Delta$ -opioid receptor function as opioid agonists and display immunomodulatory activity. *J. Neuroimmunol.* 217, 65–73
16. Mace, G. *et al.* (1999) Isolation and characterization of natural human IgG with a morphine-like activity. *Eur. J. Immunol.* 29, 997–1003
17. Mace, G. *et al.* (1999) Morphine-like activity of natural human IgG autoantibodies is because of binding to the first and third extracellular loops of the  $\mu$ -opioid receptor. *J. Biol. Chem.* 274, 20079–20082
18. Bouhla, H. *et al.* (2001) Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. *J. Immunol.* 166, 7606–7611
19. Lopalco, L. *et al.* (2000) CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 *in vivo* and neutralize the infectivity of R5 strains of HIV-1 *in vitro*. *J. Immunol.* 164, 3426–3433
20. Bouhla, H. *et al.* (2005) Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. *J. Immunol.* 174, 7202–7209
21. Bomsel, M. *et al.* (2007) Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. *AIDS* 21, 13–22
22. Barassi, C. *et al.* (2004) CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. *Blood* 104, 2205–2206
23. Pastor, C. *et al.* (2006) Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. *Blood* 107, 4825–4833
24. Elkay, K. and Casali, P. (2008) Nature and functions of autoantibodies. *Nat. Clin. Pract. Rheumatol.* 4, 491–498
25. LaMarca, B. *et al.* (2008) Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. *Hypertension* 52, 1168–1172
26. Mol, B.W.J. *et al.* (2016) Pre-eclampsia. *Lancet* 387, 999–1011
27. Ferrari, I. *et al.* (1995) Molecular mimicry between the immunodominant ribosomal protein P0 of *Trypanosoma cruzi* and a functional epitope on the human  $\beta_1$ -adrenergic receptor. *J. Exp. Med.* 182, 59–65
28. Smulski, C. *et al.* (2006) Structural basis of the cross-reaction between an antibody to the *Trypanosoma cruzi* ribosomal P2beta protein and the human beta1 adrenergic receptor. *FASEB J.* 20, 1396–1406
29. Maher, E. *et al.* (2001) A monoclonal antibody against the immunodominant epitope of the ribosomal P2beta protein of *Trypanosoma cruzi* interacts with the human  $\beta_1$ -adrenergic receptor. *Eur. J. Immunol.* 31, 2210–2216
30. Cox, C.J. *et al.* (2013) Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D<sub>2</sub> receptor: implications in human disease. *J. Immunol.* 191, 5524–5541
31. Gavalas, N.G. *et al.* (2007) The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. *J. Clin. Endocrinol. Metab.* 92, 2107–2114
32. Lancaster, E. *et al.* (2011) Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. *Neurology* 77, 1698–1701
33. Mat, A. *et al.* (2013) Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. *Neurology* 80, 1349–1350
34. Vanderlugt, C.L. and Miller, S.D. (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. *Nat. Rev. Immunol.* 2, 85–95
35. Witebsky, E. *et al.* (1957) Chronic thyroiditis and autoimmunization. *J. Am. Med. Assoc.* 164, 1439–1447
36. Matsui, S. *et al.* (1997) Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. *J. Mol. Cell. Cardiol.* 29, 641–655
37. Jahns, R. *et al.* (2004) Direct evidence for a  $\beta_1$ -adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. *J. Clin. Invest.* 113, 1419–1429
38. Siddiqui, A.H. *et al.* (2010) Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. *Hypertension* 55, 386–393
39. Zhou, C.C. *et al.* (2008) Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. *Nat. Med.* 14, 855–862
40. Sillevi-Smitt, P. *et al.* (2000) Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. *N. Engl. J. Med.* 342, 21–27
41. Sanders, J. *et al.* (2007) Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. *Thyroid* 17, 395–410
42. Sanders, P. *et al.* (2011) Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. *J. Mol. Endocrinol.* 46, 81–99
43. Morshed, S.A. *et al.* (2010) Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades. *Endocrinology* 151, 5537–5549
44. Kifor, O. *et al.* (2004) Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism. *J. Clin. Endocrinol. Metab.* 89, 548–556
45. Kifor, O. *et al.* (2003) A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. *J. Clin. Endocrinol. Metab.* 88, 60–72
46. Wallukat, G. *et al.* (1995) Anti- $\beta_1$ -adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. *J. Mol. Cell. Cardiol.* 27, 397–406
47. Li, H. *et al.* (2013) Implications of a vasodilatory human monoclonal autoantibody in postural hypotension. *J. Biol. Chem.* 288, 30734–30741
48. Fu, M.L. *et al.* (1994) Functional autoimmune epitope on  $\alpha_1$ -adrenergic receptors in patients with malignant hypertension. *Lancet* 344, 1660–1663
49. Wallukat, G. *et al.* (1999) Autoantibodies against M<sub>2</sub> muscarinic receptors in patients with cardiomyopathy display non-desensitizing agonist-like effects. *Life Sci.* 64, 465–469

50. Eftekhar, P. et al. (2000) Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT<sub>4</sub> serotonergic receptor could explain neonatal lupus congenital heart block. *Eur. J. Immunol.* 30, 2782–2790
51. Wallukat, G. et al. (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT<sub>1</sub> receptor. *J. Clin. Invest.* 103, 945–952
52. Velloso, E.P. et al. (2016) Identification of a novel agonist-like autoantibody in preeclamptic patients. *Am. J. Hypertens.* 29, 405–412
53. Tsuboi, H. et al. (2010) New epitopes and function of anti-M<sub>3</sub> muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome. *Clin. Exp. Immunol.* 162, 53–61
54. Karczewski, P. et al. (2012) Agonistic autoantibodies to the α<sub>1</sub>-adrenergic receptor and the β<sub>2</sub>-adrenergic receptor in Alzheimer's and vascular dementia. *Scand. J. Immunol.* 75, 524–530
55. Koo, N.Y. et al. (2008) Functional epitope of muscarinic type 3 receptor which interacts with autoantibodies from Sjögren's syndrome patients. *Rheumatology (Oxford)* 47, 828–833
56. Wingerl, L.M. et al. (2020) Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR. *Science* 367, 888–892
57. Fu, M.L. et al. (2000) Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. *J. Hypertens.* 18, 945–953
58. Kruse, A.C. et al. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. *Nature* 504, 101–106
59. Voigtlander, U. et al. (2003) Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M<sub>2</sub> receptor that account entirely for the M<sub>2</sub>/M<sub>5</sub> subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. *Mol. Pharmacol.* 64, 21–31
60. May, L.T. et al. (2007) Structure-function studies of allosteric agonism at M<sub>2</sub> muscarinic acetylcholine receptors. *Mol. Pharmacol.* 72, 463–476
61. Leppik, R.A. et al. (1994) Role of acidic amino acids in the allosteric modulation by galanine of antagonist binding at the M<sub>2</sub> muscarinic acetylcholine receptor. *Mol. Pharmacol.* 45, 983–990
62. Hernandez, C.C. et al. (2008) Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease. *J. Recept. Signal Transduct. Res.* 28, 375–401
63. Christopoulos, A. and Kenakin, T. (2002) G protein-coupled receptor allosterism and complexing. *Pharmacol. Rev.* 54, 323–374
64. Sterin-Borda, L. et al. (1986) Chagasic IgG binds and interacts with cardiac β adrenoceptor-coupled adenylate cyclase system. *Int. J. Immunopharmacol.* 8, 581–588
65. Limas, C.J. et al. (1989) Autoantibodies against β-adrenoceptors in human idiopathic dilated cardiomyopathy. *Circ. Res.* 64, 97–103
66. Magnusson, Y. et al. (1990) Mapping of a functional autoimmune epitope on the β<sub>1</sub>-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. *J. Clin. Invest.* 86, 1658–1663
67. Leiros, C.P. et al. (1997) Desensitization and sequestration of human M<sub>2</sub> muscarinic acetylcholine receptors by autoantibodies from patients with Chagas' disease. *J. Biol. Chem.* 272, 12989–12993
68. Jahns, R. et al. (2000) Modulation of β<sub>1</sub>-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. *J. Am. Coll. Cardiol.* 36, 1280–1287
69. Jahns, R. et al. (1999) Autoantibodies activating human β<sub>1</sub>-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. *Circulation* 99, 649–654
70. Sterin-Borda, L. et al. (1990) Human chagasic IgG interacting with lymphocyte neurotransmitter receptors triggers intracellular signal transduction. *FASEB J.* 4, 1661–1667
71. Bacman, S. et al. (1996) Circulating antibodies against rat parotid gland M<sub>3</sub> muscarinic receptors in primary Sjögren's syndrome. *Clin. Exp. Immunol.* 104, 454–459
72. De Lean, A. et al. (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. *J. Biol. Chem.* 255, 7108–7117
73. Limas, C.J. et al. (1990) Influence of anti-β-receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy. *Am. Heart J.* 119, 1322–1328
74. Magnusson, Y. et al. (1994) Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the β<sub>1</sub>-adrenoceptor with positive chronotropic effect. *Circulation* 89, 2760–2767
75. Inoue, A. et al. (2019) Illuminating G-Protein-Coupling Selectivity of GPCRs. *Cell* 177, 1933–1947 e25
76. Olsen, R.H.J. et al. (2020) TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome. *Nat. Chem. Biol.* 16, 841–849
77. Daaka, Y. et al. (1997) Switching of the coupling of the β<sub>2</sub>-adrenergic receptor to different G proteins by protein kinase A. *Nature* 390, 88–91
78. Li, H. et al. (2012) Agonistic autoantibodies as vasodilators in orthostatic hypotension: a new mechanism. *Hypertension* 59, 402–408
79. Cao, N. et al. (2018) β<sub>2</sub>-adrenergic receptor autoantibodies alleviated myocardial damage induced by β<sub>1</sub>-adrenergic receptor autoantibodies in heart failure. *Cardiovasc. Res.* 114, 1487–1498
80. Stavrakis, S. et al. (2011) Opposing cardiac effects of autoantibody activation of β-adrenergic and M<sub>2</sub> muscarinic receptors in cardiac-related diseases. *Int. J. Cardiol.* 148, 331–336
81. Zimering, M.B. and Nadkarni, S.G. (2019) Schizophrenia plasma autoantibodies promote 'biased agonism' at the 5-Hydroxytryptamine 2A receptor: neurotoxicity is positively modulated by metabotropic glutamate 2/3 receptor agonism. *Endocrinol. Diabetes Metab. J.* Published online August 14, 2019. <http://researchopenworld.com/wp-content/uploads/2019/08/EDMJ-2019-117-Mark-Zimering-USA.pdf>
82. Zimering, M.B. (2017) Diabetes autoantibodies mediate neural- and endothelial cell- inhibitory effects via 5-hydroxytryptamine- 2 receptor coupled to phospholipase C/inositol triphosphate/Ca<sup>2+</sup> pathway. *J. Endocrinol. Diabetes* Published online October 4, 2017. <http://dx.doi.org/10.15226/2374-6890/4/4/00184>
83. Makita, N. et al. (2007) An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations. *Proc. Natl. Acad. Sci. U. S. A.* 104, 5443–5448
84. Makita, N. et al. (2019) Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody. *JCI Insight* 4, e126449
85. Tutor, A.S. et al. (2007) Anti- β<sub>1</sub>-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. *Cardiovasc. Res.* 76, 51–60
86. Luttrell, L.M. et al. (1996) Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gβγ subunit-mediated activation of mitogen-activated protein kinases. *J. Biol. Chem.* 271, 19443–19450
87. Luttrell, L.M. et al. (1999) β-arrestin-dependent formation of β<sub>2</sub> adrenergic receptor-Src protein kinase complexes. *Science* 283, 655–661
88. Rajagopal, S. and Shenoy, S.K. (2018) GPCR desensitization: acute and prolonged phases. *Cell. Signal.* 41, 9–16
89. Williams, J.T. et al. (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. *Pharmacol. Rev.* 65, 223–254
90. Wallukat, G. et al. (2007) Agonistic autoantibodies against the endothelin 1 ETA - and α<sub>1</sub>-adrenergic- receptor in the sera of patients with idiopathic pulmonary arterial hypertension. (Abstract). *Circulation* 116, II\_503
91. Podlowski, S. et al. (1998) Agonistic anti-β<sub>1</sub>-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. *Circulation* 98, 2470–2476
92. Hutchings, C.J. et al. (2014) Monoclonal anti-β<sub>1</sub>-adrenergic receptor antibodies activate G protein signaling in the absence of beta-arrestin recruitment. *MAbs* 6, 246–261
93. Beltrame, S.P. et al. (2020) Impairment of agonist-induced M<sub>2</sub> muscarinic receptor activation by autoantibodies from chagasic patients with cardiovascular dysautonomia. *Clin. Immunol.* 212, 108346
94. Bian, J. et al. (2019) Limited AT<sub>1</sub> receptor internalization is a novel mechanism underlying sustained vasoconstriction induced by AT<sub>1</sub> receptor autoantibody from preeclampsia. *J. Am. Heart Assoc.* 8, e011179

95. Yu, X. *et al.* (2018) Angiotensin II type 1 receptor autoantibodies in postural tachycardia syndrome. *J. Am. Heart Assoc.* 7, e008351
96. Oakley, R.H. *et al.* (2000) Differential affinities of visual arrestin,  $\beta$ -arrestin1, and  $\beta$ -arrestin2 for G-protein-coupled receptors delineate two major classes of receptors. *J. Biol. Chem.* 275, 17201–17210
97. Strachan, R.T. *et al.* (2014) Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). *J. Biol. Chem.* 289, 14211–14224
98. Limas, C.J. *et al.* (1991) Effect of antireceptor antibodies in dilated cardiomyopathy on the cycling of cardiac  $\beta$  receptors. *Am. Heart J.* 122, 108–114
99. Mueller, A. *et al.* (2002) Pathways for internalization and recycling of the chemokine receptor CCR5. *Blood* 99, 785–791
100. Venuti, A. *et al.* (2015) ERK1-Based pathway as a new selective mechanism to modulate CCR5 with natural antibodies. *J. Immunol.* 195, 3045–3057
101. Spatola, M. *et al.* (2018) Encephalitis with mGluR5 antibodies: symptoms and antibody effects. *Neurology* 90, e1964–e1972
102. Milligan, G. (2009) G protein-coupled receptor heterodimerization: contribution to pharmacology and function. *Br. J. Pharmacol.* 158, 5–14
103. Christ, T. *et al.* (2001) Autoantibodies against the  $\beta_1$  adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. *J. Mol. Cell. Cardiol.* 33, 1515–1525
104. Mijares, A. *et al.* (2000) From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti- $\beta_2$ -adrenoceptor antibody behave as antagonists. *Mol. Pharmacol.* 58, 373–379
105. Elies, R. *et al.* (1998) Immunochemical and functional characterization of an agonist-like monoclonal antibody against the  $M_2$  acetylcholine receptor. *Eur. J. Biochem.* 251, 659–666
106. Whorton, M.R. *et al.* (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. *Proc. Natl. Acad. Sci. U. S. A.* 104, 7682–7687
107. Koehl, A. *et al.* (2019) Structural insights into the activation of metabotropic glutamate receptors. *Nature* 566, 79–84
108. Shaye, H. *et al.* (2020) Structural basis of the activation of a metabotropic GABA receptor. *Nature* 584, 298–303
109. Mao, C. *et al.* (2020) Cryo-EM structures of inactive and active GABAB receptor. *Cell Res.* 30, 564–573
110. Cremaschi, G. *et al.* (2004) Modulatory effects on myocardial physiology induced by an anti-*Trypanosoma cruzi* monoclonal antibody involve recognition of major antigenic epitopes from  $\beta_1$ -adrenergic and  $M_2$ -muscarinic cholinergic receptors without requiring receptor cross-linking. *J. Neuroimmunol.* 153, 99–107
111. Kamel, R. *et al.* (2005) Autoantibodies against the serotoninergic 5-HT<sub>4</sub> receptor and congenital heart block: a reassessment. *J. Autoimmun.* 25, 72–76
112. Limas, C.J. *et al.* (1992) Assessment of immune modulation of  $\beta$ -adrenergic pathways in human dilated cardiomyopathy: influence of methodologic factors. *Am. Heart J.* 123, 967–970
113. Nikolaev, V.O. *et al.* (2007) A novel fluorescence method for the rapid detection of functional  $\beta_1$ -adrenergic receptor autoantibodies in heart failure. *J. Am. Coll. Cardiol.* 50, 423–431
114. Tiller, T. *et al.* (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. *J. Immunol. Methods* 329, 112–124
115. Ishchenko, A. *et al.* (2018) Structural biology of G protein-coupled receptors: new opportunities from XFELs and cryoEM. *Curr. Opin. Struct. Biol.* 51, 44–52
116. Smrcka, A.V. and Fisher, I. (2019) G-protein  $\beta$  subunits as multi-functional scaffolds and transducers in G-protein-coupled receptor signaling. *Cell. Mol. Life Sci.* 76, 4447–4459
117. DeWire, S.M. *et al.* (2007)  $\beta$ -arrestins and cell signaling. *Annu. Rev. Physiol.* 69, 483–510
118. Warne, T. *et al.* (2008) Structure of a  $\beta_1$ -adrenergic G-protein-coupled receptor. *Nature* 454, 486–491
119. Iwata, M. *et al.* (2001) Autoimmunity against the second extracellular loop of  $\beta_1$ -adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy *in vivo*. *Circ. Res.* 88, 578–586
120. Buval, L. *et al.* (2006) Phenotype of early cardiomyopathic changes induced by active immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the human  $\beta$ -adrenergic receptor. *Clin. Exp. Immunol.* 143, 209–215
121. Fukuda, Y. *et al.* (2004) Autoimmunity against the second extracellular loop of  $\beta_1$ -adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. *J. Am. Coll. Cardiol.* 43, 1090–1100
122. Hong, C.M. *et al.* (2009) Effects of autoantibodies against  $M_2$  muscarinic acetylcholine receptors on rabbit atria *in vivo*. *Cardiology* 112, 180–187
123. Zhang, S. *et al.* (2015) Mitochondrial ultrastructural alterations and declined  $M_2$  receptor density were involved in cardiac dysfunction in rats after long term treatment with autoantibodies against  $M_2$  muscarinic receptor. *PLoS One* 10, e0129563
124. Ribeiro, K.C. *et al.* (2018) Immunization with plasmids encoding  $M_2$  acetylcholine muscarinic receptor epitopes impairs cardiac function in mice and induces autophagy in the myocardium. *Autoimmunity* 51, 245–257
125. Wang, F. *et al.* (2004) Passive transfer of Sjögren's syndrome IgG produces the pathophysiology of overactive bladder. *Arthritis Rheum.* 50, 3637–3645
126. Robinson, C.P. *et al.* (1998) Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome. *Proc. Natl. Acad. Sci. U. S. A.* 95, 7538–7543
127. Jin, Z. *et al.* (2011) Changes in cardiac structure and function in rats immunized by angiotensin type 1 receptor peptides. *Acta Biochim. Biophys. Sin. Shanghai* 43, 970–976
128. LaMarca, B. *et al.* (2009) Hypertension in response to autoantibodies to the angiotensin II type 1 receptor (AT1-AA) in pregnant rats: role of endothelin-1. *Hypertension* 54, 905–909
129. Wenzel, K. *et al.* (2011) Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. *Hypertension* 58, 77–84
130. Parish, M.R. *et al.* (2010) The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. *Am. J. Hypertens.* 23, 911–916
131. Parish, M.R. *et al.* (2011) Hypertension in response to AT<sub>1</sub>-AA: role of reactive oxygen species in pregnancy-induced hypertension. *Am. J. Hypertens.* 24, 835–840
132. Brewer, J. *et al.* (2013) Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. *Hypertension* 62, 886–892
133. Guo, L. *et al.* (2015) Anti-endothelin receptor type A autoantibodies in systemic lupus erythematosus-associated pulmonary arterial hypertension. *Arthritis Rheumatol.* 67, 2394–2402
134. Peter, J.C. *et al.* (2007) Antibodies against the melanocortin-4 receptor act as inverse agonists *in vitro* and *in vivo*. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 292, R2151–R2158
135. Peter, J.C. *et al.* (2009) Anti-melanocortin-4 receptor autoantibodies in obesity. *J. Clin. Endocrinol. Metab.* 94, 793–800
136. McKenzie, J.M. (1962) Fractionation of plasma containing the long acting thyroid stimulator. *J. Biol. Chem.* 237, 3571–3572
137. Valente, W.A. *et al.* (1982) Monoclonal antibodies to the thyrotropin receptor: stimulating and blocking antibodies derived from the lymphocytes of patients with Graves disease. *Proc. Natl. Acad. Sci. U. S. A.* 79, 6680–6684